The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
987
November 8, 1996
View Complete Issue         Table of Contents 2019 
A Topical Prostaglandin for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Topical Prostaglandin for Glaucoma
November 8, 1996 (Issue: 987)
Lantaoprost, a prostaglandin F2-alpha analog, has been approved by the FDA for topical treatment of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension refractory to other drugs.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Topical Prostaglandin for Glaucoma
Article code: 987b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.